Evaluation of the "symbiosys" immunoassay for the serological diagnosis of Chagas disease

Souza, Regina Maia de; Neto, Vicente Amato; Bezerra, Rita Cristina; Gakyia, Erika; Braz, Lúcia Maria Almeida

doi:10.1590/s0036-46652012000200011

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 ) including 26 different combinations of trademarks and test names. Data from 12 commercial ELISA-rec reports were extracted ( Pastini et al 1994 , Gomes et al 2001 , Gadelha et al 2003 , Pirard et al 2005 , Blejer 2006 , Chang et al 2006 , Caballero et al 2007 , Ramírez et al 2009 , Remesar et al 2009 , Villagrán et al 2009 , Añez et al 2010 , Pereira et al 2012 , Souza et al 2012) ( Fig. 1 ), including eight different combinations of trademarks and test names.…”

Section: Study Selectionmentioning

confidence: 99%

Commercial enzyme-linked immunosorbent assay versuspolymerase chain reaction for the diagnosis of chronic Chagas disease: a systematic review and meta-analysis

Brasil

Castro

2016

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

Chronic Chagas disease diagnosis relies on laboratory tests due to its clinical characteristics. The aim of this research was to review commercial enzyme-linked immunosorbent assay (ELISA) and polymerase chain reaction (PCR) diagnostic test performance. Performance of commercial ELISA or PCR for the diagnosis of chronic Chagas disease were systematically searched in PubMed, Scopus, Embase, ISI Web, and LILACS through the bibliography from 1980-2014 and by contact with the manufacturers. The risk of bias was assessed with QUADAS-2. Heterogeneity was estimated with the I2 statistic. Accuracies provided by the manufacturers usually overestimate the accuracy provided by academia. The risk of bias is high in most tests and in most QUADAS dimensions. Heterogeneity is high in either sensitivity, specificity, or both. The evidence regarding commercial ELISA and ELISA-rec sensitivity and specificity indicates that there is overestimation. The current recommendation to use two simultaneous serological tests can be supported by the risk of bias analysis and the amount of heterogeneity but not by the observed accuracies. The usefulness of PCR tests are debatable and health care providers should not order them on a routine basis. PCR may be used in selected cases due to its potential to detect seronegative subjects.

show abstract

Section: Study Selectionmentioning

confidence: 99%

Commercial enzyme-linked immunosorbent assay versuspolymerase chain reaction for the diagnosis of chronic Chagas disease: a systematic review and meta-analysis

Brasil

Castro

2016

Mem. Inst. Oswaldo Cruz

View full text Add to dashboard Cite

show abstract

“…En la actualidad, la Reacción en Cadena de la Polimerasa (PCR por sus siglas en inglés) es uno de los más recientes avances en el diagnóstico y el control del tratamiento de la enfermedad de Chagas; porque es posible detectar un parásito o un fragmento del DNA de T. cruzi en 20 µL de sangre con 99.9% de sensibilidad y 97.8% de especificidad en fase aguda. [22][23][24]…”

Section: Diagnóstico En La Fase Crónicaunclassified

Frecuencia de la infección por Trypanosoma cruzi en mujeres embarazadas y sus recién nacidos

Valdéz

View full text Add to dashboard Cite

show abstract

Evaluation of the "symbiosys" immunoassay for the serological diagnosis of Chagas disease

Cited by 2 publications

References 6 publications

Commercial enzyme-linked immunosorbent assay versuspolymerase chain reaction for the diagnosis of chronic Chagas disease: a systematic review and meta-analysis

Commercial enzyme-linked immunosorbent assay versuspolymerase chain reaction for the diagnosis of chronic Chagas disease: a systematic review and meta-analysis

Frecuencia de la infección por Trypanosoma cruzi en mujeres embarazadas y sus recién nacidos

Contact Info

Product

Resources

About